Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics
Benzinga Insights 8 months ago
Analyst Ratings
Across the recent three months, 4 analysts have shared their insights on Arcutis Biotherapeutics (NASDAQ:ARQT), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 3 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Arcutis Biotherapeutics, revealing an average target of $34.0, a high estimate of $36.00, and a low estimate of $31.00. This upward trend is evident, with the current average reflecting a 12.4% increase from the previous average price target of $30.25.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Arcutis Biotherapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tyler Van Buren | TD Cowen | Raises | Buy | $35.00 | $30.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $34.00 | $30.00 |
| Serge Belanger | Needham | Raises | Buy | $36.00 | $31.00 |
| Serge Belanger | Needham | Raises | Buy | $31.00 | $30.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcutis Biotherapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcutis Biotherapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Arcutis Biotherapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Arcutis Biotherapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Arcutis Biotherapeutics analyst ratings.
Unveiling the Story Behind Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
A Deep Dive into Arcutis Biotherapeutics's Financials
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Arcutis Biotherapeutics displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 121.69%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Arcutis Biotherapeutics's net margin is impressive, surpassing industry averages. With a net margin of 7.47%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Arcutis Biotherapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.99%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Arcutis Biotherapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.05% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.72, caution is advised due to increased financial risk.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.